Individuals with immune-mediated inflammatory disorders (IMID) are also known to be at increased risk of developing active TB, particularly after the use of tumour necrosis factor (TNF)—alpha inhibitors to treat a variety of autoimmune disease [74, 75]. Here, TNF is linked to autoimmune disease.